Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Net Cash Flow (2019 - 2025)

Historic Net Cash Flow for Madrigal Pharmaceuticals (MDGL) over the last 14 years, with Q3 2025 value amounting to $109.5 million.

  • Madrigal Pharmaceuticals' Net Cash Flow rose 14180.82% to $109.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $63.0 million, marking a year-over-year decrease of 6412.32%. This contributed to the annual value of $5.1 million for FY2024, which is 10220.35% up from last year.
  • According to the latest figures from Q3 2025, Madrigal Pharmaceuticals' Net Cash Flow is $109.5 million, which was up 14180.82% from $2.5 million recorded in Q2 2025.
  • Over the past 5 years, Madrigal Pharmaceuticals' Net Cash Flow peaked at $522.6 million during Q1 2024, and registered a low of -$261.9 million during Q3 2024.
  • Moreover, its 5-year median value for Net Cash Flow was $2.5 million (2025), whereas its average is $13.0 million.
  • As far as peak fluctuations go, Madrigal Pharmaceuticals' Net Cash Flow soared by 220932.97% in 2022, and later plummeted by 372948.61% in 2023.
  • Quarter analysis of 5 years shows Madrigal Pharmaceuticals' Net Cash Flow stood at -$12.9 million in 2021, then surged by 2209.33% to $272.2 million in 2022, then plummeted by 86.09% to $37.9 million in 2023, then plummeted by 450.41% to -$132.7 million in 2024, then skyrocketed by 182.54% to $109.5 million in 2025.
  • Its Net Cash Flow stands at $109.5 million for Q3 2025, versus $2.5 million for Q2 2025 and $83.6 million for Q1 2025.